Dual Time Point PET Imaging in Lymphoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2006 by Royal Marsden NHS Foundation Trust.
Recruitment status was  Not yet recruiting
Information provided by:
Royal Marsden NHS Foundation Trust
ClinicalTrials.gov Identifier:
First received: February 27, 2006
Last updated: October 10, 2006
Last verified: January 2006
Comparison of single time point with dual time point PET imaging in the accuracy of diagnosing active lymphoma. Biopsy results or clinical/radiological progression will be used in conjunction with the PET data.

Hodgkin's or Non-Hodgkin's Lymphoma

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Cross-Sectional

Resource links provided by NLM:

Further study details as provided by Royal Marsden NHS Foundation Trust:


Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

- Age 16 and above Diagnosis of Hodgkin's or Non-Hodgkin's lymphoma PET scan scheduled as part of management

Exclusion Criteria:

  • Pregnant or lactating Diabetes mellitus
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00297557

Contact: Dr Gary Cook 020 8661 3921

Sponsors and Collaborators
Royal Marsden NHS Foundation Trust
Principal Investigator: Dr Gary Cook Royal Marsden NHS Foundation Trust
  More Information

ClinicalTrials.gov Identifier: NCT00297557     History of Changes
Other Study ID Numbers: CCR2733 
Study First Received: February 27, 2006
Last Updated: October 10, 2006
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on May 24, 2016